CONDITIONS OF USE: The information in this database is intended to supplement, not substitute for, the expertise and judgment of healthcare professionals. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects, nor should it be construed to indicate that use of particular drug is safe, appropriate or effective for you or anyone else. A healthcare professional should be consulted before taking any drug, changing any diet or commencing or discontinuing any course of treatment.
Meta-analyses of placebo-controlled trials suggest that testosterone therapy in physiological doses is significantly associated with increased haematocrit, reduced high-density lipoprotein cholesterol and prostatic symptoms. 29 , 30 If prostate cancer has been excluded, there appears to be no increased risk of induction by testosterone therapy. There is inconsistent evidence regarding the risk of cardiovascular events. 29-31 A recent meta-analysis suggested increased cardiovascular risk and reported publication biases. 32 Long-term safety data are lacking, but recent reports more strongly suggest an increased risk of cardiovascular events in older men. 3 , 4 This has prompted the Endocrine Society to issue a warning statement. 5 The results and safety of long-term prospective controlled trials of testosterone therapy are awaited.